Core Viewpoint - The smart driving concept is gaining momentum, with several companies experiencing significant stock price increases following the announcement of new mandatory national standards for autonomous driving systems by the Ministry of Industry and Information Technology [1] Group 1: Industry Developments - The Ministry of Industry and Information Technology has organized the National Automotive Standardization Technical Committee to revise five mandatory national standards, including "Safety Requirements for Autonomous Driving Systems," and is currently soliciting public opinions on the draft [1] - Companies such as Zhejiang Shibao, Haon Automotive, Siwei Map, Wanjie Technology, Desay SV, and Zhonghaidah have seen stock price increases in response to the news [1] Group 2: Investment Recommendations - Zhongyin Securities has recommended focusing on companies related to smart driving, including Horizon Robotics and Black Sesame Intelligence for computing and chip enterprises, and companies like Zhongke Chuangda, Desay SV, Jingwei Hengrun, and Guangting Information for intelligent driving systems and domain controllers [1] - Additional recommendations include Robotaxi companies such as Pony.ai and WeRide, as well as vertical driving companies like Zhongyou Technology, Wanjie Technology, Xinbeiyang, and Beilu Zhikong [1] - Other notable mentions include Siwei Map, Xiaopeng Motors, Haohan Deep, and Alter for their contributions to the smart driving sector [1]

Group 1 - The core viewpoint of the article highlights that on February 12, brokerage firms set target prices for listed companies, with 9 instances recorded, and 6 stocks showing target price increases exceeding 20% [1] - The companies with the highest target price increases based on the latest closing prices include SMIC, Kelun Pharmaceutical, and Yaxing Integration, with increases of 45.82%, 42.98%, and 34.30% respectively [1] - The sectors represented by these companies are semiconductor, chemical pharmaceuticals, and professional engineering [1]

星际荣耀表示，本轮融资将主要用于加速可重复使用液氧甲烷运载火箭的研制与商业化进程。公司将聚 焦"陆上发射、海上回收"技术路径，加大总装总测生产能力投入，完善结构、电气、动力等核心系统试 验能力，强化海上回收能力投入，补足发射能力建设，以及强化在北京、陕西、海南、四川、广东等地 的产业布局。 2月12日，民营火箭公司星际荣耀航天科技集团股份有限公司（下称"星际荣耀"）宣布完成50.37亿元 D++轮融资。 本轮投资由同创伟业和老股东京铭资本联合领投。老股东甘泉资本、成都产投集团旗下基金（成都市重 大产业化项目二期股权投资基金有限公司）、千里马资本、鼎晖百孚、凯联资本、盈远投资、新鼎资 本、成都空港创新创业投资有限公司、率然投资等继续追投。 同时，典实资本、图灵资管、坚果资本、领阳投资、钰湖资本、玄素投资、龙芯创投、成都交子工融基 金、国中资本、建投投资、金浦投资、粤科金融、卓源亚洲等多家新机构也参与了本次投资。 星际荣耀成立于2016年，是国内成立较早的民营商业运载火箭公司，其核心团队成员主要来自于中国运 载火箭技术研究院等核心航天单位。公司董事长兼总经理彭小波曾任中国运载火箭技术研究院总体设计 部总体室主任、 ...

昨日A股 | 名称 | 最新点位 | 、涨跌幅 | | --- | --- | --- | | 上证指数 | 4134.02 | +2.04(0.05%) | | 深证指数 | 14283.0 | +122.07 (0.86%) | | 创业板指 | 3328.06 | +43.32(1.32%) | | | 日期:2月12日 制图:21投资通 | | 隔夜外盘 纽约股市三大股指2月12日下跌。截至当天收盘，道琼斯工业平均指数比前一交易日下跌669.42点，收于49451.98点， 跌幅为1.34%；标准普尔500种股票指数下跌108.71点，收于6832.76点，跌幅为1.57%；纳斯达克综合指数下跌469.32 点，收于22597.15点，跌幅为2.03%。 欧洲三大股指2月12日涨跌不一。截至当天收盘，英国富时100种股票平均价格指数12日报收于10402.44点，较前一交 易日下跌69.67点，跌幅为0.67%。法国巴黎股市CAC40指数报收于8340.56点，较前一交易日上涨27.32点，涨幅为 0.33%；德国法兰克福股市DAX指数报收于24852.69点，较前一交易日下跌3.46点，跌幅为0.0 ...

Group 1 - The company announced that its board member and CFO Gu Jun, board member and secretary Chi Mengjie, and senior vice president Cheng Junjie plan to reduce their holdings of company shares between March 17, 2026, and June 16, 2026 [1] - The planned share reductions include a maximum of 56,250 shares (not exceeding 0.0177% of the total share capital) by Gu Jun, 42,187 shares (not exceeding 0.0133% of the total share capital) by Chi Mengjie, and 45,323 shares (not exceeding 0.0143% of the total share capital) by Cheng Junjie [1]

最近，贵州贵阳谷定村办了场"蔬菜拍卖会"。跟别处不同的是，拍卖会的主持人是台湾歌手吴克群，菜 农轮番上台吆喝，台下商户纷纷举牌竞拍。 "豌豆尖下班！" "秦姐姐芹菜下班！"…… 3万斤蔬菜很快售罄，大伙儿都笑得合不拢嘴。不少网友点赞吴克群，说他有趣又有温度，"把事做进了 泥土里"。还有网友打趣，这下吴克群变"吴克穷"了。 在国台办新闻发布会上，朱凤莲就"吴克穷"的新闻回答道："我们欢迎并乐见广大台胞积极融进大陆社 会生活的更多场景，关注大陆的发展变化和民众的生活，不断传递正能量、发出好声音，让两岸的人们 更多看到彼此最美的一面。" 明星、网红是不是真"助农"，标准其实很简单，就是看农民是否真受益。 吴克群做到了这点。清晨五点半，他跟菜农挤公交，车里蔬菜堆得没处下脚，让人直观体会谋生不易； 不是拍完视频就走人，而是走访沿途村庄，了解农民种植困境；"不想只拍摄一次视频，更想帮老人卖 掉所有蔬菜"。他的视频引来50多家餐馆、超市，供需对接，不仅一次把菜卖光，还促成双方长期合 作，切实缓解菜农卖菜压力。 乡村全面振兴不可能一蹴而就，要的是久久为功。这就需要社会各方力量参与。明星用自身关注度为农 产品引流，本质上是给供 ...

Core Viewpoint - On February 13, a total of 3 companies had their restricted shares unlocked, with a combined unlock volume of 6.5482 million shares, amounting to a market value of 363 million yuan based on the latest closing price [1] Summary by Category Unlock Volume - The companies with the highest unlock volumes are Zhongkong Technology, Nanjing Commercial Travel, and Hefei Gaoke, with unlock shares of 3.9774 million, 2.1975 million, and 373,300 shares respectively [1] Unlock Market Value - In terms of unlock market value, Zhongkong Technology, Nanjing Commercial Travel, and Hefei Gaoke lead with values of 333 million yuan, 24.5024 million yuan, and 5.5998 million yuan respectively [1] Unlock Ratio - The companies with the highest unlock ratios relative to total share capital are Nanjing Commercial Travel, Zhongkong Technology, and Hefei Gaoke, with ratios of 0.7%, 0.5%, and 0.41% respectively [1]

2月12日，黄金白银深夜重挫，现货黄金跌超3%，现货白银日内跌幅一度扩大至11%。13日开盘，黄金白银延续跌势，现货黄金一度向下跌破4900美元， 最新报4912.5美元/盎司。现货白银跌超0.6%，最新报74.7美元/盎司。 除金银外，敖翀认为铜因其兼具流动性驱动与潜在的供需格局改善潜力，中长期更为看好。而对于部分已累计一定涨幅的小金属品种，则需警惕其因投机 需求主导而可能面临的价格波动风险。 敖翀最后提醒投资者，有色金属板块遵循"高PE买入、低PE卖出"的特殊估值逻辑，与传统行业相反。在当前时点，他建议投资者采取"持有"与"部分获利 了结"相结合的策略，以平衡收益与风险。 近日，针对当前黄金市场的剧烈波动与后续走向，中信证券有色金属行业首席分析师敖翀向21世纪经济报道记者分析指出，当前黄金的上涨趋势尚未完 结，流动性预期是当下驱动黄金价格走势的核心力量。此外，持续的地缘政治冲突也为黄金提供了阶段性的避险动力。 敖翀进一步分析称，随着流动性的持续释放，中国和全球经济有望在未来6-12个月内出现阶段性回暖，带动市场需求回升。在叠加供给刚性的情况下，可 能使金属价格在调整后重获支撑，并存在再创新高的可能。 ...

21世纪经济报道记者闫硕 2月11日，国家卫健委等11部门联合印发《国家基本药物目录管理办法》（简称《办法》），正式替代2015年版管理办法。 新版《办法》在多个方面进行了修订，包括增加法律政策依据、优化目录结构、完善管理机制、突出药品临床价值、规范动态 调整机制及强化监测评价，以巩固完善国家基本药物制度，保障公民基本医疗卫生服务用药需求。 我国自1982年首次公布国家基本药物目录，2009年正式建立现代基本药物制度，历经十余载发展，基药制度在破除以药补医、 规范临床合理用药、降低群众用药负担等方面发挥了基础性作用。 现行2018年版国家基本药物目录收录685种药品，但距今已有8年，与近年来医药行业创新发展、临床疾病谱变化的需求存在差 距。与此同时，药品审评审批制度改革、集采常态化推进、医保支付方式改革等行业变革，也对基药目录管理提出了新的要 求。 金春林表示，基层用药建设，并非单纯解决缺医少药的问题，核心是优中选优。化药、生物药、中医药中，代表临床主流、技 术前沿的药品，都应纳入基药目录，而非只将低价药纳入。这样既有利于分级诊疗开展、生物医药产业发展，也能完善整体医 疗秩序，避免因基层开不出药，导致分级诊疗 ...

Policy Developments - The National Health Commission announced the initiation of HPV vaccination for eligible girls starting in late February, aiming to provide free vaccination services to prevent high-risk HPV infections and reduce cervical cancer incidence [2]. Drug and Device Approvals - Fosun Pharma's subsidiary received approval for clinical trials of HLX15-SC, a monoclonal antibody for multiple myeloma treatment, with a cumulative R&D investment of approximately RMB 191.53 million expected by January 2026 [4]. - Hanyu Pharmaceutical received FDA approval for its acetate glatiramer injection, which treats relapsing multiple sclerosis, enhancing its product pipeline in the U.S. market [5]. Capital Markets - Guangji Pharmaceutical plans to raise up to RMB 600 million through a private placement of shares to repay loans and supplement working capital, pending necessary approvals [7]. - Bonasia and Zhejiang Jingxin Pharmaceutical submitted applications for listing on the Hong Kong Stock Exchange, with respective sponsors [8][9]. Clinical Innovations - A successful brain-machine interface surgery was performed in Guangxi, marking a significant advancement in clinical applications of this technology, with the market projected to reach RMB 3.2 billion by 2024, growing at 18.8% [10]. Research Developments - Researchers from the Wuhan Institute of Virology reported that the oral nucleoside prodrug VV261 effectively inhibits Chikungunya virus replication, supporting its potential new indications [11]. - Northwestern University scientists developed an advanced human spinal cord injury organoid model, providing a platform for testing new regenerative therapies [12]. Public Sentiment Alerts - McAudie announced a lawsuit against Shenyang Sixth People's Hospital over a contract dispute involving over RMB 319.82 million, with the case currently accepted by the court [14]. - The National Medical Insurance Administration listed 153 companies as "discredited," which may face restrictions on their products and services based on their credit ratings [15].